Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NP137 + unspecified PD-L1 antibody |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NP137 | NP 137|NP-137 | NP137 is a humanized monoclonal antibody against netrin-1, which blocks netrin-1 binding to its receptors, potentially leads to dependence receptor (DR)-induced apoptosis (Cancer Res 2015;75(15 Suppl):Abstract nr 2921). | ||
unspecified PD-L1 antibody | Experimental PD-L1 antibody | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 122 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05605496 | Phase II | NP137 + unspecified PD-L1 antibody NP137 + unspecified PD-1 antibody | A Multicenter, Open-label, Proof of Concept Phase II Aiming to Assess the Clinical and Biological Activity of Anti-netrin-1 (NP137) as Add on Therapy in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Immunotherapies (IMMUNONET) | Recruiting | FRA | 0 |